GW Pharmaceuticals PLC Presenting at Leerink Rare Disease Roundtable 2014 (4154S)
September 24 2014 - 2:00AM
UK Regulatory
TIDMGWP
RNS Number : 4154S
GW Pharmaceuticals PLC
24 September 2014
GW Pharmaceuticals to Present at the Leerink Rare Disease
Roundtable 2014
London, UK, 24 September 2014: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, announced that Justin Gover, GW's Chief Executive
Officer, is scheduled to present at the Leerink Rare Disease
Roundtable 2014 on Wednesday, 1 October, 2014 at 8:25 a.m. ET. The
conference will be held at the Le Parker Meridian Hotel in New York
City.
A live audio webcast of the presentation will be available
through GW's corporate website in the investor relations section
from the investor's calendar of events page at www.gwpharm.com. A
replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 26
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. This Phase 3 program has received Fast Track
Designation from the U.S. Food and Drug Administration (FDA) and is
intended to support the submission of a New Drug Application for
Sativex in cancer pain with the FDA and in other markets around the
world. GW has a deep pipeline of additional cannabinoid product
candidates, including Epidiolex(R) in the treatment of childhood
epilepsy, which has received Fast Track Designation from the FDA
for Dravet syndrome as well as Orphan Drug Designations from the
FDA in both the treatment of Dravet syndrome and Lennox-Gastaut
syndrome. GW's product pipeline also includes compounds in Phase 1
and 2 clinical development for glioma, ulcerative colitis, type 2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980
557000
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500
(U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD) +44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGURABUPCGCW
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024